From the Journals

Prior decompensation in alcohol-associated hepatitis not an ‘absolute contraindication’ for early liver transplant


 

FROM THE AMERICAN JOURNAL OF GASTROENTEROLOGY

A note of caution for early LT

About half of all liver mortality is attributable to alcoholic-associated liver disease. Corticosteroids can improve short-term survival, but there are no medications proven to increase long-term survival. That leaves liver transplant as the sole alternative for patients who don’t respond to corticosteroids.

“Programs in North America have liberalized their acceptance criteria for patients with alcoholic liver disease, and that’s resulted in large numbers of patients being transplanted who have less than 6 months abstinence. And overall, the results seem good, but I think this paper strikes an appropriate note of caution. In essence, if a patient had at least one prior episode of liver failure related to alcoholic excess and had recovered from that, and continued to drink and got into trouble again, [and then] presented for consideration for liver transplantation, the fact that they resumed alcohol use after prior episodes of decompensation suggests that they may be less-than-ideal candidates [for liver transplantation],” said Dr. Martin.

He pointed out important caveats to the study, including its retrospective nature and its inclusion of a relatively small number of patients with a history of liver decompensation. But it reinforces what physicians generally know, which is that some patients with severe alcohol use disorder also have liver failure, and they tend to fare worse than others after a liver transplant.

Still, physicians also face a conundrum because there are increasing numbers of younger patients who won’t survive if they don’t get a liver transplant. “The challenge is picking out patients who are going to be good candidates from a purely medical point of view, but have a low likelihood of resuming alcohol use after transplantation [which could injure] the new liver,” said Dr. Martin. The new study has the potential to provide some additional guidance in patient selection.

The study authors disclosed no relevant conflicts of interest. Dr. Martin has no relevant financial disclosures.

Pages

Recommended Reading

Fatty liver disease drives rise in liver cancer deaths
MDedge Internal Medicine
Fatty liver disease drives rise in liver cancer deaths
MDedge Internal Medicine
Pemvidutide promising for fatty liver disease
MDedge Internal Medicine
Low-carb, high-fat diet improves A1c, reduces liver fat
MDedge Internal Medicine
Phase 3 data shows bulevirtide benefit in hepatitis D
MDedge Internal Medicine
Statins in NAFLD: Taking a closer look at benefits
MDedge Internal Medicine
Finding HBV ‘cure’ may mean going ‘back to the drawing board’
MDedge Internal Medicine
Bulevirtide reduces hepatitis D viral load in difficult-to-treat patients
MDedge Internal Medicine
New insights into worldwide biliary tract cancer incidence, mortality
MDedge Internal Medicine
Liver cancer risk persists after direct-acting antiviral treatment for HCV
MDedge Internal Medicine